S48. Biomarker development for ipilimumab and prostate GVAX treatment

Detalles Bibliográficos
Autores principales: de Gruijl, T, Santegoets, S, Stam, A, Lougheed, S, Jooss, K, Sacks, N, Harding, T, Hege, K, Gerritsen, W, van den Eertwegh, A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Invited Speaker Presentation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072253/
http://dx.doi.org/10.1186/2051-1426-2-S2-I11
_version_ 1782322927013724160
author de Gruijl, T
Santegoets, S
Stam, A
Lougheed, S
Jooss, K
Sacks, N
Harding, T
Hege, K
Gerritsen, W
van den Eertwegh, A
author_facet de Gruijl, T
Santegoets, S
Stam, A
Lougheed, S
Jooss, K
Sacks, N
Harding, T
Hege, K
Gerritsen, W
van den Eertwegh, A
author_sort de Gruijl, T
collection PubMed
description
format Online
Article
Text
id pubmed-4072253
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40722532014-06-27 S48. Biomarker development for ipilimumab and prostate GVAX treatment de Gruijl, T Santegoets, S Stam, A Lougheed, S Jooss, K Sacks, N Harding, T Hege, K Gerritsen, W van den Eertwegh, A J Immunother Cancer Invited Speaker Presentation BioMed Central 2014-03-12 /pmc/articles/PMC4072253/ http://dx.doi.org/10.1186/2051-1426-2-S2-I11 Text en Copyright © 2014 de Gruijl et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Invited Speaker Presentation
de Gruijl, T
Santegoets, S
Stam, A
Lougheed, S
Jooss, K
Sacks, N
Harding, T
Hege, K
Gerritsen, W
van den Eertwegh, A
S48. Biomarker development for ipilimumab and prostate GVAX treatment
title S48. Biomarker development for ipilimumab and prostate GVAX treatment
title_full S48. Biomarker development for ipilimumab and prostate GVAX treatment
title_fullStr S48. Biomarker development for ipilimumab and prostate GVAX treatment
title_full_unstemmed S48. Biomarker development for ipilimumab and prostate GVAX treatment
title_short S48. Biomarker development for ipilimumab and prostate GVAX treatment
title_sort s48. biomarker development for ipilimumab and prostate gvax treatment
topic Invited Speaker Presentation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4072253/
http://dx.doi.org/10.1186/2051-1426-2-S2-I11
work_keys_str_mv AT degruijlt s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT santegoetss s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT stama s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT lougheeds s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT joossk s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT sacksn s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT hardingt s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT hegek s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT gerritsenw s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment
AT vandeneertwegha s48biomarkerdevelopmentforipilimumabandprostategvaxtreatment

Ejemplares similares